Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral chloroquine showed no clear difference in adverse events: severe compared with placebo (low certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral ciclosporin showed no clear difference in adverse events: severe compared with oral azathioprine (low certainty).
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: severe compared with oral chloroquine (low certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate may leads to higher adverse events: minor compared with oral chloroquine (low certainty).
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: severe compared with placebo (moderate certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: minor compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · health problem or population
1 finding from 1 review
Adverse events · health problem or population
1 finding from 1 review
Adverse events · individuals with sickle cell disease and a leg ulcer
1 finding from 1 review
Adverse events · individuals with sickle cell disease and a leg ulcer
It is very uncertain whether RGD peptide matrix changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse events · individuals with sickle cell disease and a leg ulcer
1 finding from 1 review
Adverse events · individuals with sickle cell disease and a leg ulcer
1 finding from 1 review
Adverse events ‐ death · adults with common mental disorders
It is very uncertain whether primary‐level worker‐led collaborative care changes adverse events ‐ death compared with usual care (very low certainty).
1 finding from 1 review
Adverse events · people with severe mental disorders
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total adverse events · participants with tophi in gout
Monthly pegloticase showed no clear difference in total adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Total adverse events · participants with tophi in gout
Lesinurad 400 mg plus febuxostat CONTINUED showed no clear difference in total adverse events compared with lesinurad 200 mg plus febuxostat CONTINUED (low certainty).
1 finding from 1 review
Total adverse events · participants with tophi in gout
Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in total adverse events compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).
1 finding from 1 review
Total adverse events · participants with tophi in gout
Pegloticase every two weeks (biweekly) showed no clear difference in total adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · parents and carers of children with complex needs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found